Stock 002399 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
10.36 CNY +9.98% Intraday chart for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. +12.36% -11.68%
29/04 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02/04 Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
MT
Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd
CI
Shenzhen Hepalink Pharmaceutical Widens 2023 Loss as Revenue Drops 24%
MT
Shenzhen Techdow Medicine Co., Ltd., Wholly-Owned Subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Exarane Obtains Approval from New Zealand Medicines and Medical Devices Safety Authority
CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces No Final Dividend for the Year Ended 31 December 2023
CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SEHK:9989) dropped from FTSE All-World Index
CI
Hepalink Pharmaceutical Gets Lifeline from Controlling Shareholder
MT
Shenzhen Hepalink Forecasts Loss in 2023; Shares Slide 4%
MT
Shenzhen Hepalink Flags Provisions of Up to 950 Million Yuan; Shares Fall 4%
MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023
CI
Hepalink Faces Regulatory Scrutiny After 12 Million Euro Telecom Fraud; Hong Kong Shares Down 3%
MT
Hepalink Pharma Unit Hit by 11.7 Million Euro Telecom Fraud
MT
Hepalink Pharma Associate HighTide Therapeutics to Debut in Hong Kong on Friday
MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SZSE:002399) dropped from Shenzhen Stock Exchange Component Index
CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(SZSE:002399) dropped from Shenzhen Stock Exchange Component A Share Index
CI
Hepalink Pharmaceutical's Profit Drops 86% in Q3; Shares Slump 4%
MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hepalink Pharmaceutical's H1 Attributable Profit Plunges on Higher Share of Losses from Associates
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002399 Stock
  4. News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.